Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor

doi:10.1016/j.intimp.2023.111412

科研成果详情

题名	Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor
作者	Yu, Jia 1; Xiong, Fen2; Xu, Yingruo2; Xu, Hanyan1; Zhang, Xi 2; Gao, Hongchang1,2; Li, Yuping1
发表日期	2024-01-25
发表期刊	INTERNATIONAL IMMUNOPHARMACOLOGY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Immune-related adverse events (irAEs) Immune checkpoint inhibitors (ICIs) Lung cancer Biomarkers Lipidomic
其他关键词	KILLER T-CELLS ; PERIPHERAL-BLOOD ; ACTIVATION ; DISEASE ; RISK
摘要	There is a lack of reliable biomarkers to predict and identify the risk of immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients undergoing immune checkpoint inhibitor (ICI) treatment. This study aims to explore potential biomarkers using lipidomics to identify and predict the risk of irAEs in NSCLC patients receiving ICI treatment. This prospective study enrolled 94 NSCLC patients with IIIB/IV stage NSCLC who underwent first-line chemotherapy in combination with ICI treatment. The prediction cohort consisted of plasma samples collected from 60 patients before ICI treatment, and the occurrence of irAE was monitored within 6 months of initiating first-line ICI therapy. The validation cohort comprised 34 patients, with plasma samples obtained from 15 patients who did not develop irAE at 6 months of ICI treatment and plasma samples collected from 19 irAE patients at the onset of irAE. Through non-targeted lipidomics and semi-targeted lipid quantification analysis, we identify 11 differentially metabolized lipids and further screened these lipids with the area under the curve (AUC) > 0.7 to predict the occurrence of irAEs in NSCLC patients following ICI treatment. The results showed that the biomarker panel consisting of 9 lipids (LPC-18:2, PC-40:6, LPC-22:6, LPC-O-18:0, PS-38:0, PC-38:6, PC-37:6, PC-36:5,LPC-17:0) exhibited a good AUC of 0.859 in the prediction and 0.940 in the validation cohort phase of the receiver operating characteristic curve; The study utilizes plasma lipidomics to develop a rapid and effective prediction model for identifying irAEs in advanced NSCLC patients who treatment with first-line chemotherapy combined with immunotherapy.
资助项目	Wenzhou Municipal Science and Technology Bureau [Y2020001]
出版者	ELSEVIER
ISSN	1567-5769
EISSN	1878-1705
卷号	127
DOI	10.1016/j.intimp.2023.111412
页数	12
WOS类目	Immunology ; Pharmacology & Pharmacy
WOS研究方向	Immunology ; Pharmacology & Pharmacy
WOS记录号	WOS:001155637200001
收录类别	SCIE ; PUBMED ; SCOPUS
在线发表日期	2023-12
URL	查看原文
PubMed ID	38160567
SCOPUSEID	2-s2.0-85181247946
通讯作者地址	[Gao, Hongchang]Institute of Metabonomics & Medical NMR,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou,325035,China
Scopus学科分类	Immunology and Allergy;Immunology;Pharmacology
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/209933
专题	附属第一医院药学院（分析测试中心）附属第二医院_核磁共振室
通讯作者	Gao, Hongchang
作者单位	1.Department of Respiratory and Critical Care Medicine,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,325035,China; 2.Oujiang Laboratory,Institute of Metabonomics & Medical NMR,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou,325035,China
第一作者单位	附属第一医院; 第一临床医学院（信息与工程学院）、附属第一医院
通讯作者单位	药学院（分析测试中心）
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Yu, Jia,Xiong, Fen,Xu, Yingruo,et al. Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor[J]. INTERNATIONAL IMMUNOPHARMACOLOGY,2024,127.
APA	Yu, Jia., Xiong, Fen., Xu, Yingruo., Xu, Hanyan., Zhang, Xi., ... & Li, Yuping. (2024). Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor. INTERNATIONAL IMMUNOPHARMACOLOGY, 127.
MLA	Yu, Jia,et al."Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor".INTERNATIONAL IMMUNOPHARMACOLOGY 127(2024).